References
- Peng L, Zhu L, Sun Y, et al. Targeting ALK rearrangements in NSCLC: current state of the art. Front Oncol. 2022;12:863461.
- Giunta EF, Signori A, West HJ, et al. Beyond crizotinib: a systematic review and meta-analysis of the next-generation ALK inhibitors as first-line treatment for ALK-translocated lung cancer. Front Oncol. 2022;12:921854.
- Felip E, Shaw AT, Bearz A, et al. Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. Ann Oncol. 2021;32(5):620–630.
- Cheng H, Perez-Soler R. Leptomeningeal metastases in non-small-cell lung cancer. Lancet Oncol. 2018;19(1):e43–e55.
- Koopman B, Groen HJM, Schuuring E, et al. Actionability of on-target ALK resistance mutations in patients with non-small cell lung cancer: local experience and review of the literature. Clin Lung Cancer. 2022;23(2):e104-15–e115.
- Lin JJ, Schoenfeld AJ, Zhu VW, et al. Efficacy of platinum/pemetrexed combination chemotherapy in ALK-positive NSCLC refractory to second-generation ALK inhibitors. J Thorac Oncol. 2020;15(2):258–265.
- De Carlo E, Schiappacassi M, Del Conte A, et al. Combination of chemotherapy and ALK inhibitors in ALK-positive NSCLC. J Thorac Oncol. 2021 May;16(5):e31-2–e32.
- Bauer TM, Shaw AT, Johnson ML, et al. Brain penetration of lorlatinib: cumulative incidences of CNS and non-CNS progression with lorlatinib in patients with previously treated ALK-positive non-small-cell lung cancer. Target Oncol. 2020;15(1):55–65.
- Ou SI, Solomon BJ, Shaw AT, et al. Continuation of lorlatinib in ALK-positive NSCLC beyond progressive disease. J Thorac Oncol. 2022;17(4):568–577.
- Hofman P. Detecting resistance to therapeutic ALK inhibitors in tumor tissue and liquid biopsy markers: an update to a clinical routine practice. Cells. 2021;10(1):168.
- Popat S, Liu G, Lu S, et al. Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3). Future Oncol. 2021;17(32):4237–4247.
- Recondo G, Mezquita L, Facchinetti F, et al. Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer. Clin Cancer Res. 2020; 26(1):242–255.
- Yoda S, Lin JJ, Lawrence MS, et al. Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer. Cancer Discov. 2018;8(6):714–729.
- Blaquier JB, Cardona AF, Russo A, et al. Next-generation sequencing using liquid biopsy in the care of patients with ALK-rearranged non-small cell lung cancer: a focus on lorlatinib. Precis Cancer Med. 2021;4:28–28.
- Pelish HE, Tangpeerachaikul A, Kohl NE, et al. NUV-655 (NVL-655) is a selective, brain-penetrant ALK inhibitor with antitumor activity against the lorlatinib-resistant G1202R/L1196M compound mutation. Cancer Res. 2021;81(13_Supplement):1468–1468.
- Murray BW, Zhai D, Deng W, et al. TPX-0131, a potent CNS-penetrant, next-generation inhibitor of wild-type ALK and ALK-resistant mutations. Mol Cancer Ther. 2021;20(9):1499–1507.